Disease Landscape and Forecast Insights

As the number of approved high-cost gene therapies increases, value assessment and novel approaches to reimbursement are rapidly gaining importance. To assist developers of gene therapies in…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by a deficiency in factor VIII. Currently, FVIII recombinant therapies, bypass agents, Hemlibra, and vasopressin receptor…

Immune thrombocytopenic purpura (ITP) is an autoimmune disease resulting in a low platelet count. Treatment of ITP involves the use of immunomodulators and corticosteroids as well as multiple…

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally grouped into three…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Clarivate Epidemiology’s coverage of osteoarthritis (OA) pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…

CIAS (e.g., impaired attention / vigilance, memory, and/or executive function) negatively impacts patients’ daily activities, occupational and social functioning, and adherence to antipsychotic…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Clarivate Epidemiology’s coverage of Rett syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate Epidemiology’s coverage of retinitis pigmentosa comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…

Glucagon-like peptide-1 (GLP-1) receptor agonists, like SC semaglutide and liraglutide, and the glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist tirzepatide have gained…